Free press releases distribution network?

Agency / Source: General Electric Company

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



New [18F]Flutemetamol Data Presented at 6th Annual Human Amyloid Imaging Conference - Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions
New [18F]Flutemetamol Data Presented at 6th Annual Human Amyloid Imaging Conference

 

PRZOOM - /newswire/ - Miami, FL, United States, 2012/01/17 - Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions. NYSE: GE

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Data presented at the 6th Annual Human Amyloid Imaging (HAI) meeting in Miami suggest that the investigational imaging agent [18F] Flutemetamol could add value to current diagnostic tools used by physicians to evaluate neurodegenerative conditions like Alzheimer’s Disease (AD). [18F]Flutemetamol is a GE Healthcare PET imaging agent in phase III development for the detection of beta amyloid.

Data presented in two abstracts from a clinical trial of [18F]Flutemetamol in patients with suspected Normal Pressure Hydrocephalus (NPH), a progressive condition associated with dementia, gait abnormalities and urinary incontinence, undergoing shunt placement, correlated [18F]Flutemetamol uptake with histopathological tissue biopsies for beta amyloid in vivo.1,2 In a third abstract from another study, researchers correlated [18F]Flutemetamol uptake and structural Magnetic Resonance Imaging (MRI) in healthy volunteers and patients with a clinical diagnosis of AD or Mild Cognitive Impairment (MCI).3 Specifically:

• [18F]-Flutemetamol uptake demonstrated a strong concordance with histopathology in subjects with NPH independent of timing and sequence of examinations.
• [18F]-Flutemetamol PET uptake showed 100 percent sensitivity and specificity with histopathology in a selected subset of subjects with NPH.
• In a subset of patients with MCI, increased [18F]-Flutemetamol uptake and decreased hippocampal volume were seen in those with progressive MCI versus those with stable MCI.

“These results support the potential role of [18F]Flutemetamol in helping physicians detect amyloid deposits in the brain,” said Jonathan Allis, MI PET Segment Leader, GE Healthcare Medical Diagnostics. “The ability to detect amyloid deposits in the brain could enable physicians to make a more accurate and earlier diagnosis of Alzheimer’s Disease.”

The accumulation of beta amyloid in the brain may play a role leading up to the degeneration of neurons and is one of several biomarkers implicated in the development of AD. Currently, AD is confirmed by histopathological identification of tissue biomarkers, including beta amyloid plaques, in post-mortem brain samples.4 Targeted imaging agents are being studied to determine their ability to help physicians detect amyloid deposition in live humans.

[18F]Flutemetamol is one part of a broad portfolio of diagnostic solutions that GE Healthcare is currently developing in the Alzheimer’s field. The company is taking a comprehensive approach to understanding AD through its ongoing research to uncover the causes, risks and physical effects of the disease. GE Healthcare’s global commitment to advance clinical knowledge and provide a variety of technologies to aid the fight in this epidemic may assist physicians in the acceleration of diagnosis and improvement of treatment decisions in all stages of the disease.

The company already offers a range of imaging modalities used by physicians to assist in the detection of AD and dementia (CT, MRI, PET, SPECT) and has been a key contributor to the Alzheimer’s Disease Neuroimaging Initiative (ADNI) since its inception. GE Healthcare also plays a key role in PredictAD, an EU-funded research project to develop solutions to enable earlier diagnosis of AD. In addition, GE has formed the Making an Impact on Neurodegenerative Diseases (MIND) Coalition, a multidisciplinary, multi-stakeholder body that aims to fill the gaps in the understanding and management of AD and Parkinson’s disease.

About GE Healthcare
GE Healthcare (gehealthcare.com) provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.

For our latest news, please visit newsroom.gehealthcare.com/.

Notes To Editors

1 Rinne JO, Wong DF, Wolk DA, Leinonen V, et al. [18F]-Flutemetamol PET Amyloid Imaging and Cortical Biopsy Histopathology in Normal Pressure Hydrocephalus: Pooled Analysis of Four Studies. 6th Annual Human Amyloid Imaging (HAI) meeting. Presented on January 12, 2012.
2 Wong D, Moghakar A, Rigamonte D, Troncoso J, et al. Prospective evaluation of [18f]-Flutemetamol for amyloid detection in the brain of living subjects with normal pressure hydrocephalus. 6th Annual Human Amyloid Imaging (HAI) meeting.
3 Thurfjell L, Lundqvist R, Lötjönen J, Koikkalainen J, et al. Combination of biomarkers: PET [18F] flutemetamol amyloid imaging and structural MRI in dementia and MCI. 6th Annual Human Amyloid Imaging (HAI) meeting.
4 Dementia: Hope Through Research. National Institute of Neurological Disorders and Stroke website. ninds.nih.gov/disorders/dementias/detail_dementia.htm. Accessed July 13, 2011.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services/Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: General Electric Company

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services/Equipment articles,
CATCH Visitors via Your Competitors Announcements!


New [18F]Flutemetamol Data Presented at 6th Annual Human Amyloid Imaging Conference

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
GE News Center |
Contact: Aleisia Gibson - GE Healthcare 
+1 609-514-6046 aleisia.gibson[.]ge.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any General Electric Company securities in any jurisdiction including any other companies listed or named in this release.

Medical Services/Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From General Electric Company / Company Profile


Read Medical Services/Equipment Most Recent Related Press Releases:

Sparta Systems Broadens Partnership with TrackWise Implementation Specialist Equality Systems
Thales Launches the Pixium Portable 3543 DR Wifi Enabled Flat Panel Detector
GE Healthcare Showcases Industry-first Technologies and Digital Solutions, Focused on Improving Outcomes, At RSNA 2016
Agfa and LCsys Team Up to Launch ABSOLUT-ID, Their Turnkey Integrated Solution for the Production of High Security ID Cards
ZOLL Technology for Improving CPR Quality to be Showcased at American Heart Association Annual Conference
AccuVein to Exhibit Leading Vein Visualization Technology at American Society for Dermatologic Surgery Annual Meeting
US Biomedical Textiles Transform Implant Device Technology by Aligning to Changes in Patient Preference Finds Frost & Sullivan
Frost & Sullivan Commends Influence Health for Constantly Evolving its Patient Engagement Products to Accelerate Market Transformation
Frost & Sullivan Awards Carestream Top Honors for OnSight 3D Extremity System
Sparta Systems Launches the Next-Generation Cloud Solution Stratas QMS

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  JobsWare.com

Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today